Bioactive Bone Substitutes Global Market Report 2026

The bioactive bone substitutes market size has grown strongly in recent years. It will grow from $2.06 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing prevalence of orthopedic and dental disorders, adoption of synthetic hydroxyapatite and calcium phosphate materials, technological advances in biomaterials, growing number of dental and orthopedic surgeries, rising awareness of bone regeneration solutions.

The bioactive bone substitutes market size is expected to see strong growth in the next few years. It will grow to $3.16 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to growing adoption of bioactive glass and polymer-based substitutes, increasing use of injectable and putty formulations, expansion of dental and orthopedic procedure volumes, rising demand for nano hydroxyapatite composites, development of collagen-ceramic composite matrices. Major trends in the forecast period include increasing adoption of injectable and paste formulations, rising demand for nano hydroxyapatite and porous scaffolds, growing focus on composite regeneration matrices, expansion of dental and orthopedic applications, rising preference for bioactive glass and polymer-based substitutes.

The rising incidence of orthopedic disorders is anticipated to propel the expansion of the bioactive bone substitutes market during the forecast period. Orthopedic disorders include a wide array of conditions impacting bones, joints, muscles, ligaments, and other components of the musculoskeletal system, frequently causing pain, limited mobility, and functional impairment. Several factors contribute to the growing occurrence of these disorders, such as aging populations, higher obesity rates, sedentary lifestyles, and injuries related to sports. Bioactive bone substitutes aid in managing orthopedic disorders by promoting natural bone regeneration, improving structural stability, speeding up the healing process in fractures and bone defects, and minimizing the necessity for secondary surgical procedures. For example, in January 2024, data from the Office for Health Improvement and Disparities, a UK government department, indicated that 18.4% of individuals aged 16 and above in the United Kingdom reported having a long-term musculoskeletal condition in 2023, compared with 17.6% in 2022. Consequently, the growing prevalence of orthopedic disorders is fueling the development of the bioactive bone substitutes market.

Leading companies operating in the bioactive bone substitutes market are focusing on developing innovative solutions, such as protein-binding synthetic bone graft substitutes, to enhance osteoinductive performance, accelerate bone regeneration, and improve clinical outcomes in orthopedic and dental applications. Protein-binding synthetic bone graft substitutes are engineered biomaterials designed to attach and retain growth factors or proteins at the implantation site, enhancing bone regeneration by stimulating natural healing and new bone formation. For example, in November 2025, Acuitive Technologies Inc., a US-based biomaterials company, launched CitreGraft, a protein-binding synthetic bone graft substitute designed to enhance protein binding and bone regeneration. CitreGraft is composed of a citrate-based polymer integrated with hydroxyapatite, enabling strong protein affinity and improved cellular signaling at the defect site. The material mimics the natural composition of bone, supports osteoconduction, and promotes early-stage bone healing by facilitating growth factor retention. It is resorbable, biocompatible, and suitable for use in orthopedic trauma, spinal fusion, and dental bone grafting procedures. Its unique citrate chemistry differentiates it from conventional calcium phosphate grafts by enhancing biological interaction and mechanical stability.

In January 2024, Biocomposites Ltd, a healthcare technology company based in the UK, completed the acquisition of Artoss GmbH for an undisclosed sum. Through this acquisition, Biocomposites intends to broaden its bone graft substitute offerings and reinforce its standing in the global Ortho biologics market by incorporating the proprietary NanoBone technology, thereby boosting its technological expertise and product diversification approach. Artoss GmbH, headquartered in Germany, is a healthcare technology company focused on delivering synthetic bone graft substitutes.

Major companies operating in the bioactive bone substitutes market are Medtronic Plc, Stryker Corporation, Zimmer Biomet Holdings Inc., Globus Medical Inc., Orthofix Medical Inc., Bioventus Inc., ZimVie Inc., Xtant Medical Holdings Inc., Biocomposites Ltd., BONESUPPORT AB, Geistlich Pharma AG, Botiss Biomaterials GmbH, Kuros Biosciences AG, Ceraver, Thommen Medical AG, Osteogenics Biomedical Inc., Curasan AG, NovaBone Products LLC, Purgo Biologics Inc., Teknimed SA.

North America was the largest region in the bioactive bone substitutes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioactive bone substitutes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioactive bone substitutes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioactive bone substitutes market consists of sales of demineralized bone matrix substitutes, tricalcium phosphate scaffolds, injectable bone void fillers, bioactive collagen-based bone substitutes, and biphasic calcium phosphate grafts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bioactive bone substitutes are natural or synthetic biomaterials intended to replace or support damaged bone while actively promoting bone regeneration. These materials interact with surrounding tissues to encourage cell attachment, growth, and new bone formation, thereby enhancing the healing process.

The prominent products of bioactive bone substitutes include calcium phosphate ceramics, hydroxyapatite-based grafts, bioactive glass materials, polymer-based substitutes, and composite regeneration matrices. Calcium phosphate ceramics are biocompatible materials designed to mimic the mineral composition of natural bone and support bone regeneration. They are developed using hydroxyapatite, tricalcium phosphate, bioactive glass, collagen, and others and are available as granules, putty, blocks, injectable formulations, and paste. Applications include orthopedic surgery, dental procedures, trauma reconstruction, synthetics, biologics or allografts, and hybrids or xenografts, serving hospitals, dental clinics, ambulatory surgical centers, and specialty orthopedic and dental distributors.

Tariffs on imported biomaterials, medical-grade polymers, and advanced ceramic components are impacting the bioactive bone substitutes market by increasing costs for manufacturers and end-users, particularly affecting calcium phosphate ceramics, hydroxyapatite-based grafts, and bioactive glass segments. Regions such as North America, Europe, and Asia-Pacific that rely on imported high-quality biomaterials are most affected. While tariffs raise production expenses, they also encourage local manufacturing, stimulate regional innovation in cost-effective biomaterials, and enhance supply chain resilience, offering potential long-term benefits.

The bioactive bone substitutes market research report is one of a series of new reports that provides bioactive bone substitutes market statistics, including bioactive bone substitutes industry global market size, regional shares, competitors with a bioactive bone substitutes market share, detailed bioactive bone substitutes market segments, market trends and opportunities, and any further data you may need to thrive in the bioactive bone substitutes industry. This bioactive bone substitutes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.